Sharon R Lewin Selected Research

COVID-19

11/2023	Interim results from a phase I randomized, placebo-controlled trial of novel SARS-CoV-2 beta variant receptor-binding domain recombinant protein and mRNA vaccines as a 4th dose booster.
11/2023	A Randomized Trial of Nafamostat for Covid-19.
6/2023	Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine.
2/2023	Anticoagulation Strategies in Non-Critically Ill Patients with Covid-19.
10/2022	Nafamostat Mesylate for Treatment of COVID-19 in Hospitalised Patients: A Structured, Narrative Review.
8/2022	Factors associated with weak positive SARS-CoV-2 diagnosis by reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR).
7/2021	Evaluation of 6 Commercial SARS-CoV-2 Serology Assays Detecting Different Antibodies for Clinical Testing and Serosurveillance.
4/2021	Multi-site assessment of rapid, point-of-care antigen testing for the diagnosis of SARS-CoV-2 infection in a low-prevalence setting: A validation and implementation study.
3/2021	Interrupting antiretroviral therapy in HIV cure trials during COVID-19: Adaptation to low transmission settings.
1/2021	Integrated immune dynamics define correlates of COVID-19 severity and antibody responses.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sharon R Lewin Research Topics

Disease

49	Infections 06/2023 - 03/2002
36	HIV Infections (HIV Infection) 10/2022 - 10/2002
27	Coinfection 03/2024 - 03/2005
12	Acquired Immunodeficiency Syndrome (AIDS) 01/2023 - 07/2005
11	Neoplasms (Cancer) 02/2022 - 01/2011
10	COVID-19 11/2023 - 01/2021
10	Latent Infection 01/2021 - 10/2011
9	Fibrosis (Cirrhosis) 03/2024 - 11/2007
9	Liver Diseases (Liver Disease) 03/2024 - 07/2008
9	Inflammation (Inflammations) 03/2024 - 11/2007
9	Viremia 01/2023 - 05/2013
8	Hepatitis B 09/2023 - 07/2002
8	Hepatitis 06/2021 - 07/2002
8	Cryptococcal Meningitis 01/2019 - 08/2013
7	Liver Cirrhosis (Hepatic Cirrhosis) 03/2024 - 09/2008
7	Chronic Hepatitis B 06/2021 - 07/2002
6	Immune Reconstitution Inflammatory Syndrome 01/2019 - 07/2008
5	Cryptococcosis 01/2019 - 08/2013
4	Disease Progression 01/2019 - 03/2005
3	Melanoma (Melanoma, Malignant) 01/2021 - 02/2015
3	Cardiovascular Diseases (Cardiovascular Disease) 08/2016 - 03/2011
2	Chronic Disease (Chronic Diseases) 01/2023 - 11/2013
2	Non-alcoholic Fatty Liver Disease 12/2019 - 01/2019
2	Virus Diseases (Viral Diseases) 01/2018 - 12/2017
1	Persistent Infection 10/2023
1	Severe Acute Respiratory Syndrome 10/2022
1	Pancreatitis 10/2022
1	Disseminated Intravascular Coagulation 10/2022
1	Ataxia (Dyssynergia) 01/2022
1	Type I Syndactyly 01/2022
1	Lethargy 01/2022
1	Confusion (Bewilderment) 01/2022

Drug/Important Bio-Agent (IBA)

18	RNA (Ribonucleic Acid)IBA 01/2023 - 02/2008
15	DNA (Deoxyribonucleic Acid)IBA 01/2023 - 12/2007
9	Proteins (Proteins, Gene)FDA Link 11/2023 - 03/2002
8	Hepatitis B e AntigensIBA 06/2021 - 09/2008
8	Tenofovir (Viread)FDA Link 01/2020 - 04/2009
7	VaccinesIBA 11/2023 - 07/2002
6	Biomarkers (Surrogate Marker)IBA 03/2024 - 01/2011
6	ChemokinesIBA 01/2023 - 12/2007
6	Antiviral Agents (Antivirals)IBA 10/2022 - 02/2003
6	AntigensIBA 07/2021 - 07/2002
5	Hepatitis B Surface Antigens (HBsAg)FDA Link 01/2020 - 07/2002
5	LipopolysaccharidesIBA 10/2016 - 04/2011
5	Lamivudine (Epivir)FDA Link 01/2016 - 07/2002
4	enhanced green fluorescent proteinIBA 12/2019 - 06/2010
4	Alanine Transaminase (SGPT)IBA 01/2016 - 07/2008
4	Lipopolysaccharide ReceptorsIBA 09/2014 - 03/2011
3	Immune Checkpoint InhibitorsIBA 02/2022 - 01/2018
3	IpilimumabIBA 10/2021 - 02/2015
3	NivolumabIBA 10/2021 - 01/2018
3	CytokinesIBA 06/2021 - 01/2011
3	InterferonsIBA 06/2021 - 01/2013
3	Messenger RNA (mRNA)IBA 01/2021 - 01/2020
3	Interleukin-10 (Interleukin 10)IBA 01/2021 - 05/2013
3	Histone Deacetylase InhibitorsIBA 09/2020 - 01/2011
3	Interleukin-7 (Interleukin 7)IBA 10/2017 - 01/2011
3	Chemokine ReceptorsIBA 01/2016 - 11/2013
2	HMGB1 Protein (HMG1)IBA 03/2024 - 01/2023
2	nafamostatIBA 11/2023 - 10/2022
2	pembrolizumabIBA 01/2022 - 01/2018
2	Disulfiram (Antabuse)FDA Link 01/2022 - 12/2015
2	Nucleic AcidsIBA 07/2021 - 06/2010
2	LuciferasesIBA 01/2021 - 01/2019
2	Interleukin-6 (Interleukin 6)IBA 01/2021 - 09/2014
2	Vorinostat FDA Link 09/2020 - 07/2013
2	LigandsIBA 01/2019 - 12/2007
2	Emtricitabine (Emtriva)FDA Link 01/2016 - 01/2010
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 09/2014 - 11/2007
2	EnzymesIBA 09/2014 - 10/2009
2	Immunoglobulins (Immunoglobulin)IBA 01/2012 - 07/2002
2	AntibodiesIBA 07/2011 - 10/2009
2	prostratinIBA 04/2011 - 01/2011
2	RacivirIBA 01/2010 - 08/2009
1	mRNA VaccinesIBA 11/2023
1	COVID-19 VaccinesIBA 11/2023
1	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 02/2023
1	AlarminsIBA 01/2023
1	venetoclaxIBA 01/2023
1	CD4 Antigens (CD4 Antigen)IBA 01/2023
1	S63845IBA 01/2023
1	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 08/2022
1	1-nitrohydroxyphenyl-N-benzoylalanine (GAL 1)IBA 01/2022
1	Galectin 1 (LGALS1)IBA 01/2022
1	RNA Splice SitesIBA 01/2022
1	Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric 01/2022
1	Neutralizing AntibodiesIBA 07/2021
1	B-Cell Activating FactorIBA 06/2021
1	Antigen-Antibody Complex (Immune Complex)IBA 01/2021

Therapy/Procedure

45	Therapeutics 03/2024 - 03/2005
23	Art Therapy 03/2024 - 10/2009
22	Highly Active Antiretroviral Therapy (HAART) 10/2017 - 02/2007
3	Immunotherapy 01/2021 - 01/2016
3	Aftercare (After-Treatment) 05/2020 - 10/2002
2	Drug Therapy (Chemotherapy) 01/2018 - 01/2016
2	Cesarean Section (Caesarean Section) 01/2012 - 08/2008
1	Withholding Treatment 01/2023
1	Stem Cell Transplantation 01/2022
1	Transplantation 01/2022
1	Intravenous Administration 01/2022